We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.97 | 0.98% | 99.79 | 100.15 | 97.99 | 97.99 | 13,351,171 | 00:58:44 |
From Feb 2023 to Feb 2025
1422 ET -- Johnson & Johnson and Merck & Co. are two of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. J&J will acquire Ambrx Biopharma in a deal with a total equity value of about $2 billion. Merck agreed to buy Harpoon Therapeutics for about $680 million. In both transactions, the per-share deal value is more than twice the Friday closing price. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
January 08, 2024 14:39 ET (19:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
